Akebia Therapeutics, Inc. (NASDAQ:AKBA) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Simply Wall StFeb 25 05:10 ET

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook

Simply Wall StFeb 22 09:02 ET

$10.7 Billion Healthcare Mobile Robots Market Outlook, 2030 by Type, End Use and Region - Akebia Therapeutics, ABB, Aethon, Omron Corp., and Amazon Lead the Competition

Yahoo FinanceFeb 7 05:52 ET

Insider Sale: CEO and President of $AKBA Sells 97,982 Shares

Quiver QuantitativeFeb 4 18:02 ET

BTIG Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Raises Target Price to $10

Moomoo NewsJan 21 07:34 ET · Ratings

Express News | Akebia Therapeutics Inc : Btig Raises Target Price to $10 From $5

ReutersJan 21 06:56 ET